Key result
An inclisiran-based treatment strategy provides a personalized approach for LDL-cholesterol management in very high cardiovascular risk patients with statin intolerance.
Why the study?
Does an inclisiran-based treatment strategy improve outcomes in very high cardiovascular risk patients with statin intolerance?
Does an inclisiran-based treatment strategy improve outcomes in very high cardiovascular risk patients with statin intolerance?
Answers are grounded in this paper and cite their sources.
This letter discusses the role of inclisiran in very high cardiovascular risk patients with statin intolerance in the context of the 2025 ESC/EAS dyslipidaemia guidelines.
Dear EditorThe 2025 focus update for dyslipidaemia of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS) highlights a more personalised strategy for LDL-cholesterol...
No takes yet. Share an insight, caveat, or question.
Pino et al. (2026) studied this question. An inclisiran-based treatment strategy provides a personalized approach for LDL-cholesterol management in very high cardiovascular risk patients with statin intolerance.
Synapse has enriched 10 related papers. Consider them for comparative context: